Key facts
- This page summarizes Martha Morrell's Form 4 filing for NeuroPace Inc (NPCE).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 31 Jan 2025, 19:16.
Martha Morrell - 29 Jan 2025 Form 4 Insider Report for NeuroPace Inc (NPCE)
- Form type
- 4
- Accepted by SEC
- 31 Jan 2025, 19:16:57 UTC
- Previous filing
- 28 Jan 2025
- Next filing
- 25 Feb 2025
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Leah Akin, Attorney-in-Fact
Source evidence
5 source fields
Reporting owner
1 detail
Key filing fact
Martha Morrell filed Form 4 for NeuroPace Inc (NPCE) on 31 Jan 2025.
Change
- Previous filing in this sequence was filed on 28 Jan 2025.
- Current net transaction value: -$4,500.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NPCE
transaction
Common Stock
Sale
- Transaction value
- $1,500
- Shares
- -100
- Change %
- -0.11%
- Price
- $15.00
- Shares after
- 86,962
- Date
- 29 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
NPCE
transaction
Common Stock
Sale
- Transaction value
- $3,000
- Shares
- -200
- Change %
- -0.23%
- Price
- $15.00
- Shares after
- 86,762
- Date
- 30 Jan 2025
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 2 footnotes
Footnote F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Footnote F2
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.